|3rd July 2020||Anthony C. J. Fernando||17,949||Exercise of derivative||$0.00|
|30th June 2020||Richard C Jr Pfenniger||3,125||Grant/award etc.||$0.00|
|30th June 2020||Brett Farabaugh||30,000||Exercise of derivative||$0.00|
|30th June 2020||Richard C Jr Pfenniger||2,403||Grant/award etc.||$0.00|
|8th June 2020||Richard C Jr Pfenniger||6,213||Grant/award etc.||$0.00|
|8th June 2020||Paul A Laviolette||22,500||Grant/award etc.||$0.00|
|8th June 2020||Paul A Laviolette||8,901||Grant/award etc.||$0.00|
|8th June 2020||Jane Ph D Hsiao||22,500||Grant/award etc.||$0.00|
|8th June 2020||Jane Ph D Hsiao||7,988||Grant/award etc.||$0.00|
|8th June 2020||Richard C Jr Pfenniger||22,500||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 2/10.
TransEnterix, Inc. is a medical device company. It focuses on commercialization of Senhance System, that digitizes laparoscopic minimally invasive surgery. The company was founded by William N. Starling in 2006.